LY6G6D: A New Member of Lymphocyte Antigen-6 Family Holds Big Opportunities in Bispecific Antibody for CRC Treatment!
 |
|||||||||||||||||||||||||||||||||||
|
The lymphocyte antigen 6 complex locus G6D (LY6G6D) is a member of the lymphocyte antigen 6 superfamily (Ly-6SF). Structurally, it shapes into a three-fingered protein domain (TFPD). As a result, Ly-6SF boasts wide range of biological functions, eg. C4.4A/LYPD3 highly expressed on squamous cell carcinoma; Lypd6 present in Wnt/β-catenin signaling pathway; Ly6e involved in viral infection like SARS-CoV-2; CD46 works together with ITG-Beta1. LY6G6D, as a fresh member of Ly-6 family, recent findings revealed its great opportunities in bispecific antibody for CRC treatment! Lately, Genentech has developed a anti-LY6G6D/CD3 bispecific antibody (LY6G6D-TDB) for CRC treatment. LY6G6D-TDB is a novel T cell-dependent bispecific antibody (TDB) targeting tumor-associated antigen LY6G6D. In mouse xenograft tumor models, LY6G6D-TDB shows anti-tumor efficacy as a single agent against established colorectal tumors. Antibodies with low specificity that cross-react with other healthy antigens might cause off-target toxicities. KRAS, HER2, EGFR, VEGF, and GPA33 are commonly reported targets for CRC. LY6G6D's specifically expression in CRC makes it an ideal target for clinical ADC applications (Click to Read More about LY6G6D). To fully support researchers and pharmaceutical companies in their research on LY6G6D in tumor and other diseases and other diseases, CUSABIO presents LY6G6D active protein (CSB-YP013246HU; CSB-YP4607MOV) to support your research on the mechanism of LY6G6D or its potential clinical value. (click for the full list of LY6G6D products: LY6G6D Protein; LY6G6D antibody). |
|||||||||||||||||||||||||||||||||||
CUSABIO appreciates the critical role that you and our products play in research since many scientists are diligently pursuing their research to further scientific innovation and discovery. Our customer service and technical support teams are equipped to remain available to help with your research needs and answer any questions.
|
